Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | $15.6M |
| Operating income | -$22.0M | -$17.9M | -$1.13M |
| Operating margin | — | — | -7.2% |
| Net income | -$21.4M | -$15.5M | -$370K |
| Net margin | — | — | -2.4% |
| EPS (diluted) | -$0.02 | -$18.62 | -$0.23 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$14.6M | -$14.7M | $77.2K |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $12.1M | $12.6M | $14.2M |
| Total assets | $28.6M | $27.6M | $28.6M |
| Total liabilities | $6.55M | $10.2M | $9.59M |
| Shareholders' equity | $22.0M | $17.5M | $19.0M |
| Retained earnings | -$162M | -$178M | -$178M |
| Shares (wtd avg diluted) | 1.47B | 832K | 1.62M |
Every figure is extracted from Neuphoria Therapeutics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.